Literature DB >> 16155108

Chronic activation of PPARalpha is detrimental to cardiac recovery after ischemia.

Nandakumar Sambandam1, Dominique Morabito, Cory Wagg, Brian N Finck, Daniel P Kelly, Gary D Lopaschuk.   

Abstract

High fatty acid oxidation (FAO) rates contribute to ischemia-reperfusion injury of the myocardium. Because peroxisome proliferator-activated receptor (PPAR)alpha regulates transcription of several FAO enzymes in the heart, we examined the response of mice with cardiac-restricted overexpression of PPARalpha (MHC-PPARalpha) or whole body PPARalpha deletion including the heart (PPARalpha-/-) to myocardial ischemia-reperfusion injury. Isolated working hearts from MHC-PPARalpha and nontransgenic (NTG) littermates were subjected to no-flow global ischemia followed by reperfusion. MHC-PPARalpha hearts had significantly higher FAO rates during aerobic and postischemic reperfusion (aerobic 1,479 +/- 171 vs. 699 +/- 117, reperfusion 1,062 +/- 214 vs. 601 +/- 70 nmol x g dry wt(-1) x min(-1); P < 0.05) and significantly lower glucose oxidation rates compared with NTG hearts (aerobic 225 +/- 36 vs. 1,563 +/- 165, reperfusion 402 +/- 54 vs. 1,758 +/- 165 nmol x g dry wt(-1) x min(-1); P < 0.05). In hearts from PPARalpha-/- mice, FAO was significantly lower during aerobic and reperfusion (aerobic 235 +/- 36 vs. 442 +/- 75, reperfusion 205 +/- 25 vs. 346 +/- 38 nmol x g dry wt(-1) x min(-1); P < 0.05) whereas glucose oxidation was significantly higher compared with wild-type (WT) hearts (aerobic 2,491 +/- 631 vs. 901 +/- 119, reperfusion 2,690 +/- 562 vs. 1,315 +/- 172 nmol x g dry wt(-1) x min(-1); P < 0.05). Increased FAO rates in MHC-PPARalpha hearts were associated with a markedly lower recovery of cardiac power (45 +/- 9% vs. 71 +/- 6% of preischemic levels in NTG hearts; P < 0.05). In contrast, the percent recovery of cardiac power of PPARalpha-/- hearts was not significantly different from that of WT hearts (80 +/- 8% vs. 75 +/- 9%). This study demonstrates that chronic activation of PPARalpha is detrimental to the cardiac recovery during reperfusion after ischemia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16155108     DOI: 10.1152/ajpheart.00285.2005

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  42 in total

Review 1.  Involvement of PPAR nuclear receptors in tissue injury and wound repair.

Authors:  Liliane Michalik; Walter Wahli
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

Review 2.  Peroxisome proliferator-activated receptors ligands and ischemia-reperfusion injury.

Authors:  Rosanna Di Paola; Salvatore Cuzzocrea
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-03-13       Impact factor: 3.000

3.  Preferential oxidation of triacylglyceride-derived fatty acids in heart is augmented by the nuclear receptor PPARalpha.

Authors:  Natasha H Banke; Adam R Wende; Teresa C Leone; J Michael O'Donnell; E Dale Abel; Daniel P Kelly; E Douglas Lewandowski
Journal:  Circ Res       Date:  2010-06-03       Impact factor: 17.367

4.  Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy.

Authors:  Stephen C Kolwicz; David P Olson; Luke C Marney; Lorena Garcia-Menendez; Robert E Synovec; Rong Tian
Journal:  Circ Res       Date:  2012-06-22       Impact factor: 17.367

Review 5.  Resveratrol and diabetic cardiac function: focus on recent in vitro and in vivo studies.

Authors:  Belma Turan; Erkan Tuncay; Guy Vassort
Journal:  J Bioenerg Biomembr       Date:  2012-04       Impact factor: 2.945

Review 6.  Metabolic therapy at the crossroad: how to optimize myocardial substrate utilization?

Authors:  Stephen C Kolwicz; Rong Tian
Journal:  Trends Cardiovasc Med       Date:  2009-08       Impact factor: 6.677

7.  Dramatic reversal of derangements in muscle metabolism and left ventricular function after bariatric surgery.

Authors:  Joshua G Leichman; Erik B Wilson; Terry Scarborough; David Aguilar; Charles C Miller; Sherman Yu; Mohamed F Algahim; Manuel Reyes; Frank G Moody; Heinrich Taegtmeyer
Journal:  Am J Med       Date:  2008-11       Impact factor: 4.965

Review 8.  PPAR transcriptional activator complex polymorphisms and the promise of individualized therapy for heart failure.

Authors:  Neville F Mistry; Sharon Cresci
Journal:  Heart Fail Rev       Date:  2008-11-08       Impact factor: 4.214

9.  Broad suppression of NADPH oxidase activity exacerbates ischemia/reperfusion injury through inadvertent downregulation of hypoxia-inducible factor-1α and upregulation of peroxisome proliferator-activated receptor-α.

Authors:  Shouji Matsushima; Junya Kuroda; Tetsuro Ago; Peiyong Zhai; Yoshiyuki Ikeda; Shinichi Oka; Guo-Hua Fong; Rong Tian; Junichi Sadoshima
Journal:  Circ Res       Date:  2013-03-08       Impact factor: 17.367

Review 10.  Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review.

Authors:  Prabal K Chatterjee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-22       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.